Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Interest Expenses (2016 - 2025)

Historic Interest Expenses for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to $6798.0.

  • China Pharma Holdings' Interest Expenses fell 65.76% to $6798.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $27166.0, marking a year-over-year increase of 11169.81%. This contributed to the annual value of $27353.0 for FY2024, which is 1052.92% down from last year.
  • As of Q3 2025, China Pharma Holdings' Interest Expenses stood at $6798.0, which was down 65.76% from $6779.0 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Interest Expenses registered a high of $333441.0 during Q4 2021, and its lowest value of -$252776.0 during Q4 2023.
  • In the last 5 years, China Pharma Holdings' Interest Expenses had a median value of $66240.0 in 2023 and averaged $55521.5.
  • Its Interest Expenses has fluctuated over the past 5 years, first skyrocketed by 20889.9% in 2021, then crashed by 36282.92% in 2023.
  • Over the past 5 years, China Pharma Holdings' Interest Expenses (Quarter) stood at $333441.0 in 2021, then tumbled by 71.16% to $96175.0 in 2022, then tumbled by 362.83% to -$252776.0 in 2023, then skyrocketed by 102.69% to $6802.0 in 2024, then dropped by 0.06% to $6798.0 in 2025.
  • Its Interest Expenses was $6798.0 in Q3 2025, compared to $6779.0 in Q2 2025 and $6787.0 in Q1 2025.